Trust Company of Vermont’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-135
Closed -$26.6K 1063
2024
Q3
$26.6K Hold
135
﹤0.01% 611
2024
Q2
$27.9K Sell
135
-13
-9% -$2.95K ﹤0.01% 563
2024
Q1
$40.1K Buy
+148
New +$35.3K ﹤0.01% 517
2023
Q4
Sell
-135
Closed -$26.5K 819
2023
Q3
$26.5K Hold
135
﹤0.01% 539
2023
Q2
$28.4K Hold
135
﹤0.01% 544
2023
Q1
$27.2K Hold
135
﹤0.01% 566
2022
Q4
$29.4K Sell
135
-23
-15% -$5.02K ﹤0.01% 543
2022
Q3
$31K Buy
158
+23
+17% +$4.96K ﹤0.01% 547
2022
Q2
$29K Buy
+135
New +$33K ﹤0.01% 533
2022
Q1
Sell
-135
Closed -$51K 400
2021
Q4
$51K Buy
+135
New +$52.5K ﹤0.01% 482
2021
Q3
Sell
-135
Closed -$50K 394
2021
Q2
$50K Hold
135
﹤0.01% 475
2021
Q1
$39K Sell
135
-8
-6% -$2.22K ﹤0.01% 495
2020
Q4
$36K Buy
143
+8
+6% +$1.91K ﹤0.01% 487
2020
Q3
$31K Buy
+135
New +$28K ﹤0.01% 481

Other funds holding CRL

Trust Company of Vermont's CRL Position: Q4 2024 in Review

Trust Company of Vermont sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 135 shares — an estimated $26.6K sold.

Trust Company of Vermont first reported a position in CRL in Q3 2020 and held it in 14 quarters. The position peaked at $51K in Q4 2021. 636 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Trust Company of Vermont reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 135 Charles River Laboratories shares in Q4 2024, an estimated $26.6K.
  • Trust Company of Vermont first reported a position in Charles River Laboratories in Q3 2020 and held it in 14 quarters.
  • Trust Company of Vermont's Charles River Laboratories position peaked at $51K in Q4 2021.
  • 636 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Trust Company of Vermont's 13F filing for Q4 2024, filed 15 Jan 2025.